Pharma Executives Need Convincing About Value-Based Contracts
Executive Summary
Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.
You may also be interested in...
Industry In The Middle: Merck's Frazier Takes A Stand, Trump Tweets Back
The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.
Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges
Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.